Zoll Acquires TherOx for Undisclosed Sum

Fresh off receiving a PMA, TherOx is now in the process of being acquired by Zoll Medical, an Asahi Kasei Group Company.  Additional terms of the deal were not disclosed. Irvine, CA-based TherOX is focused on improving the treatment of acute myocardial infarction, and markets systems to deliver SuperSaturated Oxygen (SSO2) Therapy. The therapy has been demonstrated to reduce infarct size after primary coronary intervention (PCI) with stenting in patients with left anterior descending ST-elevation myocardial infarction. When a large ischemic area of muscle damage remains following AMI, the patient condition often deteriorates into debilitating heart failure. The SuperSaturated Oxygen (SSO2) Therapy was greenlit in April and made MD+DI’s list for recent FDA-approved technologies. "Zoll and TherOx are both focused on emergency cardiac care," Neil Johnston, president of Zoll Circulation, said in a release. "This acquisition expands the Zoll product portfolio in support of excellence for patients and caregivers. No delay in door-to-balloon times and improved clinical outcomes is a combination we think physicians will find appealing. Because SSO Therapy is delivered following PCI and stenting, there is no disruption of today’s workflow in the cath lab.”
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news

Related Links:

CONCLUSION: On the basis of a broadly based research and participatory development process, a set of indicators has been developed that enables comprehensive evaluation of the regional quality of care of cross-indication, integrated care models focusing on common diseases. In order to be able to increasingly evaluate aspects of care coordination and patient orientation, health promotion as well as nursing, palliative and emergency care in the future, it would be helpful if routine data were collected or made accessible in these areas as well. PMID: 32467041 [PubMed - as supplied by publisher]
Source: Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen - Category: Health Management Tags: Z Evid Fortbild Qual Gesundhwes Source Type: research
In conclusion, low-dose intracoronary urokinase during primary PCI is associated with a more favourable 5-year outcome of patients with STEMI.
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
Although heart failure is a common complication of myocardial infarction, prognostic tools and new therapies can help manage the condition. Here are some key facts.American College of Cardiology &Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Article Source Type: news
NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson &Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided. This indication received accelera...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Abstract Blocking the mineralocorticoid receptor (MR) is one of the most effective ways of reducing blood pressure in patients with resistant hypertension and improving cardiovascular prognosis in patients with heart failure with reduced ejection fraction and left ventricular dysfunction after myocardial infarction. Blockade of the biological effects of aldosterone has mostly been achieved with spironolactone and eplerenone, the two steroidal MR antagonists currently on the market. Development of new non-steroidal dihydropyridine-based third- and fourth-generation MR antagonists is ongoing. These antagonists are h...
Source: Annales d'Endocrinologie - Category: Endocrinology Authors: Tags: Ann Endocrinol (Paris) Source Type: research
This study aimed to examine the effect of low DBP (
Source: Frontiers in Neurology - Category: Neurology Source Type: research
(Natural News) Heart attack survivors might feel apprehensive about exercising regularly. But a recent study showed that it can help prevent heart failure and increase their life expectancy over time. Published in the Journal of the American Heart Association (JAHA), the study revealed that survivors who remain physically active after a heart attack have a reduced risk...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
The treatment of hypertension in older adults is a major public health concern. Among the nearly 13 million persons in the United States aged 80 years or older, approximately 80% have high blood pressure (BP). Hypertension is the most potent modifiable risk factor for cardiovascular disease in older adults and has been strongly associated with stroke, myocardial infarction, heart failure, peripheral artery disease, kidney failure, and dementia. Thus, defining optimal strategies for managing elevated BP in older individuals is a high priority.
Source: JAMA - Category: General Medicine Source Type: research
ConclusionFXa inhibition with apixaban does not influence pathological cardiac remodelling after MI. These data do not support the use of FXa inhibitor in HF patients with the aim to amend the severity of HF.Graphical Abstract
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
AbstractAn increase in left ventricular volumes between baseline and follow-up imaging is the main criteria for the quantification of left ventricular remodelling (LVR) after ST-elevation myocardial infarction (STEMI), but without consensual definition. We aimed to review the criteria used for the definition of LVR based on cardiac magnetic resonance imaging (CMR) in STEMI patients. A systematic literature search was conducted using MEDLINE and the Cochrane Library from January 2010 to August 2019. Thirty-seven studies involving 4209 patients were included. Among these studies, 30 (81%) used a cut-off value for defining LV...
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
More News: Cardiology | Emergency Medicine | Heart | Heart Attack | Heart Failure | Medical Devices | Mergers and Aquisitions